Flashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal Cancer

Article Tools FLASHBACK FOREWORD Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES JCO Flashback: Exploring an Effective Drug Combination for Colorectal Cancer (2000). November 15, 2023 Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer. November 15, 2023 ARTICLE CITATION DOI: 10.1200/JCO.23.01109 Journal of Clinical Oncology - published online before print November 15, 2023 PMID: 37967514 Flashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal Cancer Robert J. Mayer, MD1,2xRobert J. MayerSearch for articles by this author Show More 1Former Associate Editor, Journal of Clinical Oncology, Alexandria, VA2Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA https://doi.org/10.1200/JCO.23.01109 First Page Full Text PDF Figures and Tables © 2023 by American Society of Clinical OncologyTHE TAKEAWAYIn 2000, de Gramont et al1 published data showing that the addition of oxaliplatin to infusional fluorouracil/leucovorin (FOLFOX) enhanced the likelihood of disease regression and prolonged median progression-free survival when used as the initial treatment for measurable, unresectable/metastatic colorectal cancer. The use of FOLFOX was subsequently extended to the adjuvant treatment of stage III colorectal cancer and several other types of gastrointestinal malignancies, in addition to becoming the backbone for the fluorouracil, leucovorin, irinotecan, and oxaliplatin regimen in the treatment of pancreatic cancer. It remains a widely used standard today, in large part because of this trial.AUTHOR'S DISCLOSURES OF POTENTIAL CONFLICTS OF INTERESTFlashback Foreword: Oxaliplatin Plus LV5FU2 in Colorectal CancerThe following represents disclosure information provided by the author of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).Robert J. MayerConsulting or Advisory Role: EisaiNo other potential conflicts of interest were reported. Companion JCO Flashback: Exploring an Effective Drug Combination for Colorectal Cancer (2000) Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer